Intravitreal triamcinolone for diabetic macular edema: Comparison of 1, 2, and 4 mg

Retina

Volumn 28, Issue 6, 2008, Pages 825-830

  Hauser, David ^a   Bukelman, Amir ^a   Pokroy, Russell ^a   Katz, Haia ^a   Len, Ariela ^a   Thein, Ran ^a   Parness Yossifon, Rehut ^a   Pollack, Ayala ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

Author keywords

Diabetes mellitus; Diffuse diabetic macular edema; Intravitreal triamcinolone dose comparison; Macular cysts

Indexed keywords

TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EARLY TREATMENT DIABETIC RETINOPATHY STUDY; EYE; EYE EXAMINATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; SCORING SYSTEM; SIDE EFFECT; THICKNESS; TREATMENT DURATION; VISUAL ACUITY; DIABETIC RETINOPATHY; INJECTION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RETINA MACULA EDEMA; TREATMENT OUTCOME; VITREOUS BODY;

AGED; DIABETIC RETINOPATHY; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 47749116519     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318165767e     Document Type: Article

References (24)

1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1-9.
2. Photocoagulation for diabetic macular oedema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-1806.
3. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991;98:1594-1602.
4. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
5. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcino-lone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-160.
6. Jonas JB, Harder B, Kamppeter BA. Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004;138:970-977.
7. Jonas JB, Akkoyun I, Kreissig I, et al. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol 2005;89:321-326.
8. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.
9. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-225.
10. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-2049.
11. Bakri SJ, Beer PM. Intravitreal triamcinolone injection for diabetic macular oedema: a clinical and fluorescein angiographic case series. Can J Ophthalmol 2004;39:755-760.
12. Lam DS, Chan CK, Mohamed S, et al. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. Eye 2005;19:885-890.
13. Lam DS, Chan CK, Tang EW, et al. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Clin Experiment Ophthalmol 2004;32:569-572.
14. Ozkiris A, Evereklioglu C, Erkilic K, et al. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular oedema. Eur J Ophthalmol 2004;14:543-549.
15. Chieh JJ, Roth DB, Liu M, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina 2005;25:828-834.
16. Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006;142:794-799.
17. Lam DS, Chan CK, Mohamed S, et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91:199-203.
18. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29:27-33.
19. Chan A, Duker JS. A standardized method for reporting changes in macular thickening using optical coherence tomography. Arch Ophthalmol 2005;123:939-943.
20. Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802-806.
21. Diabetic Retinopathy Clinical Research Network: Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-536.
22. Macky TA, Helmy D, El Shazly N. Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch Clin Exp Ophthalmol 2007;245: 817-824.
23. Morrison VL, Koh HJ, Cheng L, et al. Intravitreal toxicity of the Kenalog vehicle (benzyl alcohol) in rabbits. Retina 2006; 26:339-344.
24. Lang Y, Zemel E, Miller B, Perlman I. Retinal toxicity of intravitreal Kenalog in albino rabbits. Retina 2007;27:778-788.